Key result
Higher 3D LV-GLS is linked to ~15% lower risk of cardiovascular events in Fabry disease.
Why the study?
Fabry disease manifests as a phenocopy of hypertrophic cardiomyopathy, but the relationship of echocardiographic 3D LV strain to heart failure severity, myocardial scar, and long-term prognosis was unclear.
Does 3D echocardiographic left ventricular strain correlate with heart failure severity and myocardial scar and predict long-term cardiovascular prognosis in patients with Fabry disease?
Cohort (n=75)
Investigator blinded to echocardiographic results evaluated the clinical events
No
Does 3D echocardiographic left ventricular strain correlate with heart failure severity and myocardial scar and predict long-term cardiovascular prognosis in patients with Fabry disease?
This first evaluation of 3D echocardiographic strain in Fabry disease demonstrates that 3D LV-GLS reflects NT-proBNP-defined heart failure severity and independently predicts long-term cardiovascular outcomes, while localized posterolateral 3D circumferential strain identifies CMR-confirmed myocardial fibrosis.
Answers are grounded in this paper and cite their sources.
3D LV-GLS may aid risk stratification in Fabry disease; leaves open its incremental value over standard measures in prospective validation.
AIMS: Fabry disease (FD) is a multisystemic lysosomal storage disorder caused by a defect in the alpha-galactosidase A gene that manifests as a phenocopy of hypertrophic cardiomyopathy. We assessed the echocardiographic 3D left ventricular (LV) strain of patients with FD in relation to heart failure severity using natriuretic peptides, the presence of a cardiovascular magnetic resonance (CMR) late gadolinium enhancement scar, and long-term prognosis. METHODS AND RESULTS: 3D echocardiography was feasible in 75/99 patients with FD [aged 47 ± 14 years, 44% males, LV ejection fraction (EF) 65 ± 6% and 51% with hypertrophy or concentric remodelling of the LV]. Long-term prognosis (death, heart failure decompensation, or cardiovascular hospitalization) was assessed over a median follow-up of 3.1 years. A stronger correlation was observed for N-terminal pro-brain natriuretic peptide levels with 3D LV global longitudinal strain (GLS, r = -0.49, P < 0.0001) than with 3D LV global circumferential strain (GCS, r = -0.38, P < 0.001) or 3D LVEF (r = -0.25, P = 0.036). Individuals with posterolateral scar on CMR had lower posterolateral 3D circumferential strain (CS; P = 0.009). 3D LV-GLS was associated with long-term prognosis [adjusted hazard ratio 0.85 (confidence interval 0.75-0.95), P = 0.004], while 3D LV-GCS and 3D LVEF were not (P = 0.284 and P = 0.324). CONCLUSION: 3D LV-GLS is associated with both heart failure severity measured by natriuretic peptide levels and long-term prognosis. Decreased posterolateral 3D CS reflects typical posterolateral scarring in FD. Where feasible, 3D-strain echocardiography can be used for a comprehensive mechanical assessment of the LV in patients with FD.
No takes yet. Share an insight, caveat, or question.
Marek et al. (2023) conducted a cohort in Fabry disease (n=75). 3D left ventricular global longitudinal strain (3D LV-GLS) by 3D speckle-tracking echocardiography vs. 3D LV global circumferential strain (3D LV-GCS) and 3D LV ejection fraction (3D LVEF) was evaluated on Composite of all-cause death, heart failure decompensation, or cardiovascular hospitalization (HR 0.85, 95% CI 0.75-0.95, p=0.004). 3D left ventricular global longitudinal strain (3D LV-GLS) independently predicted long-term cardiovascular prognosis in Fabry disease.
Synapse has enriched 10 related papers. Consider them for comparative context: